Is Compounded Tirzepatide Going Away? What Patients Need to Know in 2026

Key Takeaways

• The FDA removed tirzepatide from its drug shortage list on October 2, 2024, with enforcement of the rule following a court-ordered timeline.
• Mass-produced 503B compounded tirzepatide largely ended in early 2025 once the appeals process resolved.
• 503A compounding pharmacies can still prepare tirzepatide for individual patients with a specific prescription, when a provider has documented clinical need.
• Personalized formulations (different doses, B12 add-ins, allergen-free preparations) remain available because they meet the regulatory definition of a medically necessary compound.
• Patients on compounded tirzepatide should plan ahead, ask their provider about a personalized prescription pathway, and be wary of overseas suppliers selling "research" peptides.

Direct answer (40-60 words)

Mass-produced compounded tirzepatide largely ended after the FDA removed tirzepatide from the shortage list on October 2, 2024. Personalized 503A compounded tirzepatide remains legal when a licensed provider documents clinical reasons (different dose, ingredient changes, allergy considerations) for a specific patient. The landscape has narrowed but not disappeared.

Table of contents

1. The 30-second answer
2. The shortage list timeline and what it changed
3. 503A vs 503B compounding (and why the difference matters now)
4. What "personalized prescribing" actually means
5. Why the FDA made this change
6. The patient impact
7. What's still available in 2026
8. The risk of overseas "research" peptides
9. FAQ

The shortage list timeline and what it changed

Tirzepatide was added to the FDA Drug Shortages List in December 2022 after Eli Lilly couldn't keep up with demand for Mounjaro. Once a drug is on the shortage list, federal law (FD&C Act sections 503A and 503B) allows compounding pharmacies to prepare the active ingredient for patients, filling the supply gap.

By mid-2024, manufacturing capacity had caught up with demand. Lilly publicly stated in mid-2024 that supply could meet projected demand and asked the FDA to delist tirzepatide. The FDA agreed and announced removal from the shortage list on October 2, 2024.

A trade group representing 503B outsourcing facilities filed suit. The federal court allowed compounding to continue temporarily during the litigation but ultimately ruled in favor of the FDA. By March 2025, the legal process had largely concluded, and mass production by 503B facilities ended.

What changed:

• 503B outsourcing facilities (large-scale FDA-registered compounders that ship pre-prepared vials to clinics and pharmacies) can no longer make tirzepatide as a stocked product.
• 503A pharmacies (traditional state-licensed compounding pharmacies that fill individual prescriptions) cannot prepare a "copy" of an FDA-approved drug.
• 503A pharmacies can still prepare a personalized formulation when there's a documented clinical reason it differs meaningfully from the FDA-approved product.

The third point is where most compounded tirzepatide prescriptions land in 2026.

503A vs 503B compounding (and why the difference matters now)

Two regulatory tracks exist for compounding pharmacies, and the rules are not the same.

503A pharmacies are state-licensed traditional compounding pharmacies. They prepare medications for individual patients in response to a specific prescription. Volume is limited, and each preparation is meant to be patient-specific. Section 503A of the Federal Food, Drug, and Cosmetic Act allows them to compound under the supervision of a licensed pharmacist, but they cannot mass-produce drugs that are commercially available in identical form.

503B outsourcing facilities are FDA-registered larger compounders that can prepare medications in bulk without patient-specific prescriptions, intended for office stock at clinics and hospitals. They must comply with current good manufacturing practices (cGMP) similar to drug manufacturers. Section 503B was created in 2013 after the New England Compounding Center meningitis outbreak.

When tirzepatide was on the shortage list, both 503A and 503B pharmacies could legally prepare it under shortage exemptions. After delisting, those exemptions ended. 503B facilities can no longer stock it as a generic compound. 503A pharmacies retain a narrower path: personalized preparations for individual patients when the prescription specifies something different from the commercial product.

The practical difference for patients: telehealth platforms that previously sourced from 503B outsourcing facilities had to either move to 503A pharmacy networks, transition patients to brand-name products, or close.

What "personalized prescribing" actually means

A 503A pharmacy can compound tirzepatide if the prescription is for a personalized preparation that's clinically meaningfully different from FDA-approved Mounjaro or Zepbound. The FDA has not published a precise list of what qualifies, but examples that compounding pharmacy industry guidance considers acceptable include:

• Different concentration or dose strength that isn't available as a commercial product. Mounjaro pens come in 2.5, 5, 7.5, 10, 12.5, and 15 mg doses. A prescription for a custom dose like 6 mg or 11 mg might qualify if there's a clinical reason.
• Combination preparations with B12, methionine, or other added ingredients prescribed for a specific patient need.
• Allergen-free preparations for patients with documented sensitivity to inactive ingredients in the commercial product.
• Alternative delivery formats like a multi-dose vial when the patient cannot self-administer with a pen due to a documented condition.

What does not qualify under the post-shortage rules:

• An identical copy of Mounjaro or Zepbound at a lower price
• A "personalized" prescription that's actually just a workaround for cost
• Bulk preparations made before any patient prescription

The line between legitimate personalization and "regulatory cosmetic" varies by state board interpretation. Compounding pharmacies and prescribing providers are still calibrating where the line is in practice.

Why the FDA made this change

Three reasons in the FDA's public statements (FDA Drug Shortages program updates, 2024):

Reason 1: Supply has caught up. Eli Lilly invested billions in tirzepatide manufacturing capacity through 2023 and 2024. By the time of the delisting decision, the agency concluded supply could meet projected demand for both the diabetes (Mounjaro) and obesity (Zepbound) indications.

Reason 2: Compounded versions don't have the same safety oversight. FDA-approved tirzepatide goes through full nonclinical and clinical testing, including the SURMOUNT trials (Jastreboff et al., NEJM 2022) and SURPASS trials (Frias et al., NEJM 2021). Compounded versions don't, by design. As long as they were filling a genuine shortage, the trade-off was justified. Once supply normalized, the FDA's view was that patients should have access to the tested product where possible.

Reason 3: Quality concerns at some compounders. The FDA issued multiple warning letters to compounding facilities in 2023 and 2024 for sterility issues, mislabeling, and use of non-pharmaceutical-grade active ingredients sourced from unverified suppliers. While most compounders operate to high standards, the variability across the industry was a contributor to the agency's reasoning.

The FDA did not make a finding that all compounded tirzepatide is unsafe. The change is regulatory, tied to the shortage status, not a safety determination on individual products.

The patient impact

If you're on compounded tirzepatide in 2026, three scenarios apply.

Scenario A: Your provider has transitioned you to a personalized 503A prescription. This is the most common path. Your prescription specifies a custom dose or formulation that 503A pharmacies can still prepare. Continuity of care is largely unchanged, though pricing may have shifted upward as 503A volumes are smaller than the previous 503B model.

Scenario B: Your provider has transitioned you to brand-name Zepbound or Mounjaro. If clinically appropriate and affordable, this is the cleanest path. Manufacturer savings programs (LillyDirect for self-pay patients, the Zepbound savings card for commercially insured patients) brought self-pay pricing for the lowest dose pens to roughly $399 to $499 per month in 2025. Higher doses cost more.

Scenario C: Your provider has paused therapy. Some patients have paused while transitioning between options. Stopping tirzepatide typically leads to appetite rebound within 4 to 8 weeks and partial weight regain over the following months, per the SURMOUNT-4 withdrawal extension data.

If you've been receiving tirzepatide from a telehealth platform that has gone quiet on the regulatory question, ask directly: "Is my prescription being filled by a 503A pharmacy with personalized formulation, or by a 503B facility?" The answer matters for whether your supply will continue.

What's still available in 2026

Still available through 503A pharmacies (with valid personalized prescription):

• Custom-dose tirzepatide vials at strengths not commercially available
• Tirzepatide combined with B12 or B-complex
• Tirzepatide in preservative-free preparations for documented sensitivities

Still available commercially:

• Mounjaro (FDA-approved tirzepatide for type 2 diabetes), 6 dose strengths
• Zepbound (FDA-approved tirzepatide for chronic weight management), 6 dose strengths
• LillyDirect self-pay pricing on Zepbound vials at all doses
• Manufacturer savings programs for commercially insured patients (eligibility varies)

No longer broadly available:

• Generic-strength compounded tirzepatide from 503B facilities
• Mass-marketed "compounded tirzepatide for $199/month" offerings that were common in 2023 to 2024
• Stockpiles from 503B outsourcing facilities

The compounded supply is narrower, more expensive, and more clinically justified than it was 18 months ago. Patients with clear medical reasons for a personalized formulation still have access. Patients seeking compounded versions purely for price savings have fewer options.

The risk of overseas "research" peptides

A predictable consequence of the regulatory tightening was an increase in marketing of "research-grade" tirzepatide from overseas peptide vendors, often labeled "not for human use" to skirt FDA jurisdiction.

These products carry meaningful risks:

• No quality control. A 2024 FDA import alert listed multiple overseas peptide suppliers for products contaminated with bacterial endotoxins above pharmaceutical limits.
• Variable potency. Independent testing of "research" peptides published in 2023 found dose variation of plus or minus 30% from labeled strength on average.
• Wrong active ingredient. Mass spectrometry analysis of seized samples in 2024 found products labeled as tirzepatide that contained semaglutide, a different peptide entirely, or no active ingredient at all.
• No legal recourse. Buying from overseas vendors places the transaction outside U.S. consumer protection.

If your goal is continuity of care on tirzepatide and the personalized 503A path doesn't fit your situation, the safer alternatives are commercial Zepbound or Mounjaro through manufacturer programs, brand-name semaglutide products, or a transition plan with your provider. Overseas "research" peptides are not a substitute for prescription medication.

FAQ

Is compounded tirzepatide still legal in 2026? Personalized 503A compounded tirzepatide is legal when prepared in response to a valid prescription that specifies a clinically meaningful difference from commercial Mounjaro or Zepbound. Mass-produced 503B compounded tirzepatide largely ended after the FDA removed tirzepatide from the shortage list in October 2024.

Why did the FDA remove tirzepatide from the shortage list? The FDA determined that Eli Lilly's manufacturing capacity could meet projected U.S. demand. Removal from the list ended the shortage exemptions that allowed widespread compounding. The decision was administrative, not a safety determination.

Will I lose access to my compounded tirzepatide? Possibly, depending on your prescription type. If your prescription is a generic-strength copy from a 503B facility, that supply has largely ended. If your prescription is from a 503A pharmacy with a personalized formulation, supply may continue.

What's the difference between 503A and 503B compounding? 503A pharmacies are state-licensed and prepare medications for individual patients in response to specific prescriptions. 503B outsourcing facilities are FDA-registered, can produce in bulk for office stock, and operate under different rules. After tirzepatide's delisting, only 503A pharmacies can compound it, and only for personalized prescriptions.

Can I still get a $199 monthly compounded tirzepatide subscription? Most of the low-cost subscription offerings that flourished in 2023 and 2024 sourced from 503B facilities and have either ended or transitioned to brand-name products. Personalized 503A compounded tirzepatide is generally more expensive than those legacy offerings.

Is brand-name Zepbound now my only option? No. Personalized 503A compounded tirzepatide is still available through pharmacies and providers operating in that pathway. Other GLP-1 medications including semaglutide products (which remain on the FDA shortage list as of early 2026) and dual-approved options may also fit.

How much does brand-name Zepbound cost in 2026? Self-pay through LillyDirect was priced at $399 to $499 per month for the 2.5 mg and 5 mg vial strengths in 2025. Higher doses run higher. Commercial insurance with a manufacturer savings card can bring out-of-pocket cost as low as $25 per month for eligible patients.

Can I import tirzepatide from another country? Personal importation of prescription drugs is generally not permitted under FDA rules, with very narrow exceptions for limited personal supplies of medications not available in the U.S. Tirzepatide is FDA-approved and available in the U.S., so importation does not qualify under those exceptions.

Are "research" peptides a safe alternative? No. Products labeled "for research use only" from overseas vendors are not subject to U.S. quality standards. Independent testing has found variable potency, contamination, and incorrect active ingredients in these products. They should not be substituted for prescription tirzepatide.

Why is compounded semaglutide still available but tirzepatide isn't? Semaglutide remains on the FDA shortage list as of early 2026, which preserves the compounding exemptions for it. Tirzepatide was removed from the list in late 2024, ending the equivalent exemptions for that drug specifically. The two situations track different supply trajectories.

What should I ask my provider right now? Three questions: which pharmacy is filling your prescription, whether it's 503A personalized or 503B, and what the transition plan is if your current supply pathway changes. Knowing the answer in advance helps you plan ahead.

Does compounded tirzepatide work the same as Zepbound? Properly compounded tirzepatide uses the same active ingredient as Zepbound, so the mechanism is the same. Compounded versions have not undergone the same FDA review as Zepbound, and individual potency varies depending on the compounding pharmacy's quality systems.

Sources

1. U.S. Food and Drug Administration. FDA Drug Shortages Database. Tirzepatide injection status update, October 2, 2024.
2. U.S. Food and Drug Administration. Section 503A vs 503B Compounding Pharmacy Differences. Compounding regulatory framework guidance.
3. Federal Food, Drug, and Cosmetic Act, sections 503A and 503B.
4. Eli Lilly and Company. Tirzepatide manufacturing capacity statements, investor communications, 2024.
5. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
6. Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503-515.
7. SURMOUNT-4 trial. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2024.
8. U.S. Food and Drug Administration. Warning letters to compounding pharmacies, 2023-2024 archive.
9. United States Pharmacopeia. Chapter <797> Pharmaceutical Compounding, Sterile Preparations.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly.